Literature DB >> 31753931

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.

Ramzi Abboud1, Ezhilarasi Chendamarai1, Michael P Rettig1, Kathryn M Trinkaus2, Peter A Riedell1, Camille N Abboud1, Armin Ghobadi1, Iskra Pusic1, Keith Stockerl-Goldstein1, Mark A Schroeder1, Ravi Vij1, Peter Westervelt1, John F DiPersio1, Geoffrey L Uy3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31753931      PMCID： PMC7395277          DOI： 10.3324/haematol.2019.236810

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.

Authors:  Kellie R Machlus; Stephen K Wu; Prakrith Vijey; Thomas S Soussou; Zhi-Jian Liu; Eran Shacham; T J Unger; Trinayan Kashyap; Boris Klebanov; Martha Sola-Visner; Marsha Crochiere; Joseph E Italiano; Yosef Landesman
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

2.  XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.

Authors:  Parvathi Ranganathan; Trinayan Kashyap; Xueyan Yu; Xiaomei Meng; Tzung-Huei Lai; Betina McNeil; Bhavana Bhatnagar; Sharon Shacham; Michael Kauffman; Adrienne M Dorrance; William Blum; Deepa Sampath; Yosef Landesman; Ramiro Garzon
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

3.  Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Authors:  M Wattad; D Weber; K Döhner; J Krauter; V I Gaidzik; P Paschka; M Heuser; F Thol; T Kindler; M Lübbert; H R Salih; A Kündgen; H-A Horst; P Brossart; K Götze; D Nachbaur; C-H Köhne; M Ringhoffer; G Wulf; G Held; H Salwender; A Benner; A Ganser; H Döhner; R F Schlenk
Journal:  Leukemia       Date:  2017-01-19       Impact factor: 11.528

4.  A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Authors:  Ramiro Garzon; Michael Savona; Rachid Baz; Michael Andreeff; Nashat Gabrail; Martin Gutierrez; Lynn Savoie; Paul Morten Mau-Sorensen; Nina Wagner-Johnston; Karen Yee; Thaddeus J Unger; Jean-Richard Saint-Martin; Robert Carlson; Tami Rashal; Trinayan Kashyap; Boris Klebanov; Sharon Shacham; Michael Kauffman; Richard Stone
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

5.  Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Authors:  Dimitri A Breems; Wim L J Van Putten; Peter C Huijgens; Gert J Ossenkoppele; Gregor E G Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van der Lelie; Marc A Boogaerts; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2005-01-04       Impact factor: 44.544

6.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

7.  High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.

Authors:  Peter Westervelt; Andrew A Lane; Jessica L Pollock; Kristie Oldfather; Matthew S Holt; Drazen B Zimonjic; Nicholas C Popescu; John F DiPersio; Timothy J Ley
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

8.  XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.

Authors:  Jimi Kim; Elizabeth McMillan; Hyun Seok Kim; Niranjan Venkateswaran; Gurbani Makkar; Jaime Rodriguez-Canales; Pamela Villalobos; Jasper Edgar Neggers; Saurabh Mendiratta; Shuguang Wei; Yosef Landesman; William Senapedis; Erkan Baloglu; Chi-Wan B Chow; Robin E Frink; Boning Gao; Michael Roth; John D Minna; Dirk Daelemans; Ignacio I Wistuba; Bruce A Posner; Pier Paolo Scaglioni; Michael A White
Journal:  Nature       Date:  2016-09-28       Impact factor: 49.962

9.  A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.

Authors:  Amy Y Wang; Howard Weiner; Margaret Green; Hua Chang; Noreen Fulton; Richard A Larson; Olatoyosi Odenike; Andrew S Artz; Michael R Bishop; Lucy A Godley; Michael J Thirman; Satyajit Kosuri; Jane E Churpek; Emily Curran; Kristen Pettit; Wendy Stock; Hongtao Liu
Journal:  J Hematol Oncol       Date:  2018-01-05       Impact factor: 17.388

10.  KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.

Authors:  J Etchin; A Berezovskaya; A S Conway; I A Galinsky; R M Stone; E Baloglu; W Senapedis; Y Landesman; M Kauffman; S Shacham; J C Y Wang; A T Look
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528
View more
  3 in total

1.  Improvement of Myelopoiesis in Cyclophosphamide-Immunosuppressed Mice by Oral Administration of Viable or Non-Viable Lactobacillus Strains.

Authors:  Andrés Gramajo Lopez; Florencia Gutiérrez; Lucila Saavedra; Elvira Maria Hebert; Susana Alvarez; Susana Salva
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

2.  Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms.

Authors:  Christopher J Walker; Hua Chang; Leah Henegar; Trinayan Kashyap; Sharon Shacham; Josh Sommer; Michael J Wick; Joan Levy; Yosef Landesman
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

3.  A multiparametric niche-like drug screening platform in acute myeloid leukemia.

Authors:  Reinaldo Dal Bello; Justine Pasanisi; Romane Joudinaud; Matthieu Duchmann; Bryann Pardieu; Paolo Ayaka; Giuseppe Di Feo; Gaetano Sodaro; Clémentine Chauvel; Rathana Kim; Loic Vasseur; Laureen Chat; Frank Ling; Kim Pacchiardi; Camille Vaganay; Jeannig Berrou; Chaima Benaksas; Nicolas Boissel; Thorsten Braun; Claude Preudhomme; Hervé Dombret; Emmanuel Raffoux; Nina Fenouille; Emmanuelle Clappier; Lionel Adès; Alexandre Puissant; Raphael Itzykson
Journal:  Blood Cancer J       Date:  2022-06-24       Impact factor: 9.812
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.